Clinical Trial Detail

NCT ID NCT01876212
Title Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hussein Tawbi
Indications

melanoma

Therapies

Dasatinib

Age Groups: adult

No variant requirements are available.